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Binding proteins for insulin-like growth factors (IGFs)
IGF-I and IGF-II, known as IGFBPs, control the
distribution, function and activity of IGFs in various
cell tissues and body fluids. Insulin-like growth factor-
binding protein-5 (IGFBP-5) is known to modulate the
stimulatory effects of IGFs and is the major IGF-
binding protein in bone tissue. We have expressed two
N-terminal fragments of IGFBP-5 in Escherichia coli;
the first encodes the N-terminal domain of the protein
(residues 1–104) and the second, mini-IGFBP-5, com-
prises residues Ala40 to Ile92. We show that the
entire IGFBP-5 protein contains only one high-affinity
binding site for IGFs, located in mini-IGFBP-5. The
solution structure of mini-IGFBP-5, determined by
nuclear magnetic resonance spectroscopy, discloses a
rigid, globular structure that consists of a centrally
located three-stranded anti-parallel β-sheet. Its scaffold
is stabilized further by two inside packed disulfide
bridges. The binding to IGFs, which is in the nanomolar
range, involves conserved Leu and Val residues local-
ized in a hydrophobic patch on the surface of the
IGFBP-5 protein. Remarkably, the IGF-I receptor
binding assays of IGFBP-5 showed that IGFBP-5
inhibits the binding of IGFs to the IGF-I receptor,
resulting in reduction of receptor stimulation and
autophosphorylation. Compared with the full-length
IGFBP-5, the smaller N-terminal fragments were less
efficient inhibitors of the IGF-I receptor binding of
IGFs.
Keywords: IGFBP-5/insulin-like growth factor/IGF
binding/IGF receptor binding/IGF receptor structure
Introduction
The insulin-like growth factor (IGF) system consists of
IGF-I and IGF-II, the IGF-I and IGF-II/M-6-P receptors,
IGF-binding proteins (IGFBPs), IGFBP cleaving proteases
and an acid-labile subunit (ALS). IGF-I and IGF-II exhibit
a broad range of effects on embryonic and fetal growth,
development and metabolism (Stewart and Rotwein,
1996). There is also an impressive body of evidence
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accumulated over the past 10 years that clearly indicates
a pivotal role for the IGF system in cancer and in several
metabolic disorders such as neurodegenerative diseases
and osteoporosis (Walsh, 1995; Rosen et al., 1997; Werner
and LeRoth, 1998). IGFs mediate their pleiotropic actions
by binding to and activating IGF receptors. IGF action is
modulated by a group of six IGF-binding proteins that
form high-affinity complexes with both IGF-I and IGF-II
(Clemmons, 1997; Rajaram et al., 1997). IGFBPs prevent
the insulin-like effects of IGFs, control the half-life of
IGFs in blood, act as carrier proteins for IGFs and
determine the distribution of IGFs between tissues and
extracellular fluids. The affinity of IGFBPs for IGFs is
controlled by phosphorylation, glycosylation and, most
importantly, by specific proteolysis (Conover, 1995).
Insulin-like growth-factor-binding protein-5 (IGFBP-5),
the subject of the present study, is known to potentiate
the action of IGF-I on smooth muscle cells, fibroblasts or
osteoblasts (Bautista et al., 1991). The binding of IGFBP-
5 to the extracellular matrix or heparins leads to the 8- to
17-fold decrease of the IGFBP-5 affinity for IGF-I and to
enhancement of the biological action of IGF-I on the cells
(Jones et al., 1993; Arai et al., 1996; Campbell et al., 1997).
Three-dimensional structures of IGF-I and IGF-II are
known (Cooke et al., 1991; Terasawa et al., 1994).
However, with the exception of a domain resolution model
for the IGF binding to IGFBP-3 (Spencer and Chan,
1995), there is as yet no structural information available
on any protein of the IGFBP family. IGFBPs are proteins
of 216–289 residues, with mature IGFBP-5 consisting of
252 residues (Rajaram et al., 1997). All IGFBPs share a
common domain organization. The highest conservation
is found in the N- (residues 1 to ~100) and C- (from residue
170) terminal cysteine-rich regions. Twelve conserved
cysteines are found in the N-terminal domain and six in
the C-terminal domain. The central, weakly conserved
part (L-domain) contains most of the cleavage sites for
specific proteases (Chernausek et al., 1995). Several differ-
ent fragments of IGFBPs have been described and bio-
chemically characterized so far (Spencer and Chan, 1995).
It is accepted generally that the high-affinity IGF-binding
site is located in the N-terminal domain (Zapf et al.,
1990; Andress et al., 1993; Chernausek et al., 1995;
Fowlkes et al., 1995; Durham et al., 1997; Hashimoto
et al., 1997), although Spencer and Chan (1995), Wang
et al. (1988) and Ho et al. (1997) suggested that
IGFBP-3 and IGFBP-2 contain at least two binding
determinants, one in the N- and one in the C-terminal
domain.
In the present paper we have performed the nuclear
magnetic resonance (NMR) characterization of IGFBP-5
and its two N-terminal fragments and describe their IGF-
binding properties. Furthermore, we show that IGFBP-5
inhibits the IGF-induced activation of the IGF-I receptor.
Structural basis of the IGFBP-5 binding to IGFs
Fig. 1. Overview of the IGFBP-5 fragments. Three fragments, 1–94,
95–134 and 135–246, were obtained by proteolysis of a full-length
IGFBP-5 (residues 1–252). Additionally, two recombinant fragments in
E.coli were produced [His-tag 10 kDa IGFBP-5(1–104) and mini-
IGFBP-5].
We also present the three-dimensional structure of the
smallest IGFBP-5 domain (mini-IGFBP-5) that contains
the primary high-affinity site for IGFs. Based on this
structure, a model for the complex between mini-
IGFBP-5 and IGF-II that satisfies the currently available
structural and biochemical data is proposed.
Results
Proteolysis of IGFBP-5 and construction of
recombinant N-terminal fragments
The full-length human IGFBP-5 was purified from Escher-
ichia coli (Mohan et al., 1995) and subjected to limited
proteolysis with endoproteinase Asp N. As indicated in
Figure 1, three fragments were produced by proteolysis,
the N-terminal fragment containing residues 1–94 (the
10 kDa fragment), the C-terminal fragment with residues
135–246 and a central 4 kDa fragment which spans
residues 95–134. During purification of IGFBP-5, an
additional 4 kDa fragment was identified which starts at
Ala40 and retains binding affinity to IGFs with high
affinity (data not shown). All fragments were analysed by
SDS–PAGE, N-terminal sequencing and mass spectro-
scopy. Based on these results, we constructed and
expressed two fragments of IGFBP-5 in E.coli. The first
fragment, the His-tag 10 kDa IGFBP-5, encloses the
complete N-domain of the protein (residues Leu1 to
Thr104 plus 13 N-terminal residues of the His-tag) and
the second fragment, mini-IGFBP-5, comprises residues
Ala40 to Ile92 (plus two N-terminal vector residues).
IGF-binding properties of IGFBP-5 and its
fragments
IGF-binding properties of different fragments were
quantitatively analyzed by BIAcore biosensor measure-
ments (Table I; Figure 2). Neither the C-terminal fragment
(residues 135–246) nor the mid-regional fragment
(residues 95–134) had detectable affinities for immobilized
IGF-I or IGF-II (data not shown). Affinities of the 10 kDa
fragment (derived from Asp N cleavage) and recombin-
ant mini-IGFBP-5 were in the nanomolar range, 10- to
200-fold reduced compared with the full-length IGFBP-5
(Table I). For all binding species the association is very
fast. Thus the difference in affinity between the truncated
and full-length peptides is mainly caused by an increase
in the rate of dissociation of the fragments. Mini-
IGFBP-5 and the 10 kDa fragment have similar affinities
for IGFs (Table I). The small difference in affinity of the
fragments is predominantly due to faster binding of mini-
IGFBP-5 to IGFs with very fast kinetics that were beyond
the resolution of the instrument. The higher affinity of
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Table I. BIAcore data
Analyte Ligand kon koff KA KD
106/Ms 1/s 1/M nM
IGFBP-5 IGF-I 1.2 4.410–3 2.7108 3.7
IGF-II 7.1 5.410–4 1.31010 0.08
mini- IGF-I 5.1 1.910–1 2.7107 37
IGFBP-5 IGF-II 7.5 4.710–2 1.6108 6.3
10kDa IGF-I 1.9 3.010–1 6.3106 158
IGFBP-5 IGF-II 1.5 2.410–2 6.3107 16
Summary of the kinetic data of IGF-I and IGF-II binding to IGFBP-5,
10 kDa IGFBP5(1–92), and mini-IGFBP-5. General curve fitting was
performed for 250, 50, 10 and 2 nM of analyte. A 1:1 binding with
mass transfer was used as a model. IGF-I and IGF-II was immobilized
on a biosensor.
the full-length IGFBP-5 is caused by the much slower
dissociation rate of the complex. Variation of the flow rate
clearly demonstrated mass transport effects (data not
shown). Therefore we used the highest flow rate of the
instrument and low ligand concentrations to minimize
rebinding and mass transport, but this may not have been
sufficient to exclude these effects completely.
IGFBP-5 modulation of the IGFs’ interactions with
the IGF-I receptor
Both IGF-I and IGF-II bind to the IGF-I receptor with
high affinity (KD  1.5 and 3.0 nM, respectively; Loddick
et al., 1998). The truncated proteins, as well as the full-
length IGFBP-5, display higher inhibitory potency for
IGF-II than for IGF-I; for example, IGFBP-5 has a lower
IC50 value for IGF-II (10 pM) than for IGF-I (40 pM).
As shown in Figure 3A, preincubation of 125I-IGF-II
with increasing concentrations of full-length IGFBP-5
resulted in an IGFBP-5 concentration-dependent inhibition
of the IGF-II binding to the IGF-I receptor and complete
inhibition is observed as soon as IGFBP-5 is in excess of
IGF-II (Table II). Similar results were obtained when
measuring the influence of the IGFBP-5–IGF complex
formation on IGF-mediated stimulation of the IGF-I
receptor autophosphorylation (Figure 3B; Table II). These
data clearly demonstrate that IGFBP-5 functions as a
natural inhibitory protein for IGFs. Mini-IGFBP-5 and the
10 kDa N-terminal fragment showed only weak inhibitory
potency. As summarized in Table II, a 103-fold excess of
these fragments was needed to block IGF-II binding to its
receptor. In addition, even a 1 μM concentration of the
fragments was not sufficient to inhibit the IGF-II-mediated
receptor phosphorylation at the IGF-II concentration of
10–8 M.
Biophysical properties of IGFBP-5 and its
fragments
The IGFBP-5 fragments shown in Figure 1 were also
checked for their folding properties with NMR. NMR
spectroscopy is a powerful technique for studying folded–
unfolded equilibria in macromolecules (Wu¨thrich, 1986;
Zhang and Forman-Kay, 1995). An unfolded protein shows
a small dispersion of chemical shifts of amino acid residues
(Wu¨thrich, 1986). This is particularly true for amide
resonances which are clustered at ~8.5 p.p.m. in the proton
spectrum of an unfolded protein. NMR spectra of the
C-terminal fragment (residues 134–246) revealed sharp
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Fig. 2. The IGF binding of IGFBP-5 and its fragments. (A) Sensograms showing the binding of IGFBP-5 to a sensor chip SA coated with 5 nM
biotinylated IGF-I and IGF-II. The binding of IGFBP-5 was measured at a concentration of 250 nM at a flow rate of 100 μl/min. (B) 10 kDa
IGFBP-5. (C) mini-IGFBP-5.
resonance lines at 8.5 p.p.m., which together with the
resonance intensity pattern of the up-field-shifted aliphatic
resonances (0.3 to –0.2 p.p.m.) versus the intensity of the
bulk aliphatic resonance lines at 0.8 p.p.m., allowed us to
estimate that ~40% of the C-terminal fragment was in a
random coil conformation. The 4 kDa fragment (residues
93–134) exhibited an NMR spectrum typical for an
unstructured peptide. This is in agreement with the sugges-
tion that the central, weakly conserved L-domain has a
high conformational flexibility (Spencer and Chan, 1995).
Mini-IGFBP-5 and the His-tag 10 kDa N-terminal frag-
ment IGFBP-5(1–104) are folded in solution, as can be
seen from the HSQC spectra of Figure 4A, which clearly
shows that mini-IGFBP-5 and both parts 1–39 and 40–92
of the IGFBP-5 (1–104) are structured.
The two recombinant N-terminal constructs showed the
presence of higher than monomeric species in solution.
Spectra for 1H, 15N and 13C exhibited line widths broader
than those expected for monomeric proteins at concentra-
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tions between 0.2 and 1.5 mM. At pH 3.7, 15N relaxation
and other line width data indicated a possible monomeric–
dimeric equilibrium for mini-IGFBP-5 and higher oligo-
merization states for the 10 kDa construct 1–104. As a
result of this increased aggregation, the quality of NOESY
(two-dimensional nuclear Overhauser effect spectroscopy)
spectra of the His-tag 10 kDa IGFBP-5 were such that
they were not suitable for a detailed NMR analysis. At
pH 6.5, a dramatic increase of line widths (1H amide line
widths 35 Hz) suggested higher oligomerization states for
both peptides. Dilution of the proteins from 1.0 to 0.4 mM
had only a small beneficial effect on line widths. Therefore,
oligomerization properties of mini-IGFBP-5 were studied
with NMR using mini-IGFBP-5 prepared by mixing 1:1
the 13C/15N/1H-labelled and 12C/14N/1H-unlabelled protein.
With this sample it is possible to determine intermolecular
NOE interactions provided that defined and NMR long-
lived oligomers are present in solution (Zwahlen et al.,
1997). No intermolecular NOEs (nuclear Overhauser
Structural basis of the IGFBP-5 binding to IGFs
effect) could be detected for mini-IGFBP-5 in the NMR
spectra, indicating that the increase of NMR line widths
is due to unspecific aggregation of the protein. We also
checked for the presence of multiple conformations or non-
native S–S states by NOESY, TOCSY (total correlation
Fig. 3. Inhibition of IGF-II-mediated responses by different IGFBP-5
peptides. (A) Inhibition of 125I-IGF-II binding by different IGFBP-5
peptides to the intact NIH 3T3 cells expressing IGF-IR. (B) Inhibition
of IGF-II-stimulated IGF-IR phosphorylation by preincubation of
IGF-II with increasing concentrations of IGFBP-5. Confluent
monolayers of NIH 3T3 cells expressing IGF-IR were starved for
48 h. After stimulation with either 10–8 M IGF-II alone (lane 2) or in
a combination of different concentrations of IGFBP-5 (lanes 3–9) or
no hormone (lane 1) for 10 min at 37°C, medium was removed, and
cells were lysed for 10 min on ice. After lysis, the insoluble material
was separated by centrifugation, and the supernatant was analysed by
Western blotting with a monoclonal anti-phosphotyrosine antibody
after SDS–PAGE. Molecular weight standard as indicated.
Table II. Inhibitory characteristics of full-length IGFBP-5 and N-terminal fragments
Analyte Ligand IC50 value using 510
–12 M [125I]IGF-I IC50 value using 510
–9 M IGF-I
or IGF-II for binding to IGF-IR or 10–8 M IGF-II to stimulate IGF-IR autophosphorylation
IGFBP-5 IGF-I 410–11 10–9–510–9
IGF-II 110–11 510–9–10–8
mini- IGF-I 110–7 10–6
IGFBP-5 IGF-II 110–8 10–6
10kDa IGF-I 310–7 10–6





Receptor binding analyses were performed as described in Figure 3A, receptor phosphorylation analyses as described in Figure 3B. IC50  molar
concentration of IGFBP-5, fragments or IGFs (cold) required to reduce the binding of iodinated ligand to receptors or the stimulation of IGF-IR
autophosphorylation by 50%.
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spectroscopy) and ROESY (rotating frame Overhauser
effect spectroscopy) spectra. Mini-IGFBP-5 has four
cysteines that are known to participate in disulfide
bridges (see below). In principle, a mixture of three
different S–S pairs was possible for these four cysteines
because their side-chains are all located in the center of the
protein structure and are close to each other (Figure 5A).
However, all NMR and other biophysical data (elution in
one sharp peak from the reversed-phase HPLC analysis,
unfolding and refolding properties) indicated that a
single mini-IGFBP-5 molecule had a unique conformation
in solution. Therefore, we concluded that the NMR line
broadening is due to unspecific aggregation. Adding mild
detergents, such as CHAPS, or increasing salt concentra-
tion did not improve the spectra. Lowering the pH of the
sample from pH 6.5 to 3.7 proved to be a single determin-
ing factor in reducing the extent of aggregation. Formation
of the complex between mini-IGFBP-5 and IGFs leads to
additional broadening of all NMR resonances to such an
extent that no quantitative NMR structural evaluation of
the spectra was possible. So far, an attempt to crystallize
the complex has not been successful.
Three-dimensional structure of mini-IGFBP-5
Stereo views of the three-dimensional structure of mini-
IGFBP-5 calculated from 385 approximate distance and
84 torsion angle constraints are shown in Figure 5A and
B. Table III shows data for qualities of the calculated
structures. A total of 90 structures was calculated by a
simulated annealing protocol (Bru¨nger and Nilges,
1993). A family of the 20 best structures was selected
using total energies as selection criteria (Figure 5A). All
structures satisfy the experimental constraints with small
deviations from idealized covalent geometry (Table III).
The average atomic root mean square deviations (r.m.s.d.)
for heavy atoms of residues Ala40–Pro62 and Pro69–
Tyr86 among the structures were 0.32  0.16 Å for the
backbone atoms and 0.83  0.40 Å for all atoms. For the
whole protein (excluding Arg86 to Ile92) the r.m.s.d.
values were 0.68  0.42 Å for the backbone atoms and
1.69  0.65 Å for all atoms.
Three short anti-parallel β-strands (residues 46–47,
58–61 and 78–82) together with two cysteine bridges are
responsible for a compact and uniquely defined fold
of mini-IGFBP-5. A solvent-exposed loop between Pro62
W.Kalus et al.
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and Pro69 is the least precisely defined segment of the
structure and five C-terminal residues of mini-IGFBP-5
are unstructured. Relaxationmeasurements for 15N indicate
that the backbone of the variable loop 62–69 does not
exhibit any fast picosecond time-scale motions; instead
the loop residues in the IGF uncomplexed mini-IGBP-5
show contributions from slower millisecond exchange
processes (data not shown). IGF complex formation,
however, imposes rigidification of this loop. The cysteine
bonds are formed between Cys47 and Cys60, and Cys54
and Cys80. These S–S pairings fit the experimental data
best, displaying, for example, characteristic NOE patterns
between β–β methylene groups of these residues (Klaus
et al., 1993), although, as mentioned above, the S–S
isomerization or different S–S pairing would cause little
structural modification. Our assignment of the disulfide
bond pattern in mini-IGFBP-5 is in agreement with the
pattern of the two bridges recently determined for IGFBP-3
by peptide mapping (Hashimoto et al., 1997).
Mapping the binding site of IGF-II on mini-IGFBP-5
Mapping the binding site of IGF-II on mini-IGFBP-5 with
NMR was accomplished by monitoring chemical shift
changes (Craik and Wilce, 1997) of the backbone and
most of the side-chain proton and carbon atom resonances
(Figures 4B, C and 6). Since mini-IGFBP-5 forms a tight
complex with IGF-II (and IGF-I), numerous residues in
Fig. 4. 1H-15N HSQC spectrum of the uniformly 15N-labelled mini-IGFBP-5 and 10 kDa IGFBP-5 (1–104) at pH 4.5. (A) Overlay of 1H-15N HSQC
spectra of free mini-IGFBP-5 (black) and free 10 kDa IGFBP-5 (blue). Small shifts are observed for resonances of residues 41–90 (arrows). Some
peaks (circles) could not be assigned for the 10 kDa IGFBP-5. The cross-peak from His71 is visible at pH 5.0. Ser39 belongs to the thrombin
cleavage site of mini-IGFBP-5 and therefore is not present in the HSQC of 10 kDa IGFBP-5. (B) Overlay of 1H-15N-HSQC spectra of free (black)
and complexed (red) mini-IGFBP-5. Arrows connect resonances of free and complexed forms. (C) Overlay of 1H-15N HSQC spectra of
complexed mini-IGFBP-5 (red) and complexed 10 kDa IGFBP-5 (green). Almost no difference in chemical shifts is observed for the assigned
resonances.
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the HSQC spectra show pairs of well-resolved peaks
corresponding to free and IGF-II-bound states upon addi-
tion of IGF-II to the 15N-labelled mini-IGFBP-5, for
example, in the ratio 0.5:1.0, respectively. The largest
IGF-induced chemical shifts were observed for residues
Val49, Tyr50, Pro62 and Lys68 to Leu75 (Figure 6). These
induced shifts (especially the SN parameters, see Materials
and methods) are directly proportional to the strength of
the intermolecular interaction of the residues in the binding
cleft in the first approximation. These residues form the
major IGF-binding region of mini-IGFBP-5. As can be
seen from Figure 6, the binding site residues can be
determined from independent NMR titrations of different
types of nuclei (1HN, 15N or 13C; see Figure 6). In addition,
an assignment of several intermolecular IGF-II–IGFBP-5
NOEs for Val49, Leu70, Leu73 and Leu74 was obtained
from the half-filter NMR spectra (Zwahlen et al., 1997)
using the 13C/15N-labelled mini-IGFBP-5 complexed to
unlabelled IGF-II. NOESY patterns of free and
bound mini-IGFBP-5 are similar, indicating little change
in the structure of mini-IGFBP-5 upon binding to IGF-II.
The 15N NMR IGF-II titration was also carried out for
the recombinant His-tag 10 kDa IGFBP-5(1–104). As can
be seen in Figure 4, it was possible to assign most of the
HSQC peaks of the free and complexed mini-IGFBP-5
fragment in the HSQC spectra of the free and complexed
10 kDa IGFBP-5(1–104). The remaining unassigned peaks
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in HSQC spectra of 10 kDa IGFBP-5(1–104) arise from
the His-tag, the N-terminal 39 residues and 12 additional
C-terminal residues. They also show very small changes
in chemical shifts between free and complexed 10 kDa
IGFBP-5(1–104). Differences in amide proton and nitro-
gen chemical shifts between the N-terminal 10 kDa
domain and the mini-IGFBP-5 are small, especially for
the complexed peptides. Therefore, we conclude that the
first 39 residues of IGFBP-5 constitute an independent
domain (with three proposed disulfide bridges) that has no




Mini-IGFBP-5 has a compact and globular 3D structure
whose scaffold is secured by an inside packing of
two cysteine bridges stabilized further by a three-stranded
β-sheet. The mini-IGFBP-5 fold seems to be unique;
we found no similar fold in database searches. The
present NMR study shows unequivocally that the primary
IGF-binding site comprises residues Val49, Tyr50, Pro62
and Lys68 to Leu75, exclusively located in the mini-
IGFBP-5 domain of the N-terminal part of IGFBP-5. No
binding is expected in the first N-terminal 39 residues of
IGFBP-5, as shown by the NMR titration and BIAcore
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Fig. 5. The three-dimensional structure of mini-IGFBP-5. Residues showing large chemical shifts upon IGF complexation are red, residues with
additional intermolecular NOEs to IGFs are yellow. The cysteine bridges are green. Figures were created using the MOLMOL program (Koradi
et al., 1996). (A) Stereo view of the backbone atoms (N, Cα, C) of the final ensemble of 20 mini-IGFBP-5 structures best fit to N, Cα and C atoms
of residues 40–62 and 69–86. (B) Ribbon drawing of mini-IGFBP-5 showing its β-sheet, the cysteine bridges and the residues composing the
hydrophobic patch. (C) Solid surface model of mini-IGFBP-5.
Fig. 6. Differences in chemical shifts of free and IGF-complexed mini-IGFBP-5. Difference of chemical shifts of the IGF-II-complexed and -
free mini-IGFBP-5 for all residues. Shift differences are scaled and combined with different sets (see experimental procedures): all, corresponds to
the combination of carbon, nitrogen and proton shifts (averaged); proton, to the combination of Hα, Hβ, Hγ, H δ, and H N shifts, carbon to Cα and
Cβ-shifts; nitrogen, to 15N shifts; proton-nitrogen, to 1HN and 15N shifts; and proton-carbon, to proton and 13C. Non-assigned signals appear as zero.
Large shifts indicate residues involved in the IGF binding.
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Fig. 7. Model of IGF-II binding to mini-IGFBP-5. The arrows connect binding areas. Phe48 of IGF-II docks to the hydrophobic patch of mini-
IGFBP-5 composed of Val49, Leu70 and Leu74. Glu6 of IGF-II interacts with Lys68 of the hydrophilic and variable loop of mini-IGFBP-5. Surfaces
are colored according to hydrophobic properties (red, hydrophobic; white, neutral; blue, hydrophilic). Computational results obtained using Insight II
(Insight, 1995).
binding measurements of mini-IGFBP-5 and the larger
10 kDa fragments that include the 39 N-terminal residues.
For IGFBP-2, it was shown that Tyr60 (which corresponds
to Tyr50 in IGFBP-5) was protected against iodination
upon binding of IGFBP-2 to IGF-II (Hobba et al., 1996)
suggesting that this residue is close to the IGF-binding
site, in agreement with our data. The C-terminal fragment
(residues 135–246) and the mid-regional fragment
(residues 95–134) bind neither IGF-I nor IGF-II.
The affinities of mini-IGFBP-5 and of the longer 10 kDa
fragment to IGF-I and IGF-II are in the nanomolar range;
the interaction of mini-IGFBP-5 with IGFs is very strong.
A life-time of the IGF-II–mini-IGFBP-5 complex is 5 s
(koff  1.910 s–1; Table I). The BIAcore measurements
showed that these affinities are 10- to 200-fold lower
compared with those of the full-length IGFBP-5, which
agrees well with the reported reduced affinities of other
C-terminally truncated fragments of IGFBP-3 (Clemmons,
1993) and IGFBP-5 (Andress et al., 1993). The higher
affinity of the full-length IGFBP-5 is most probably
caused by secondary interactions of the residues from the
neighbouring to mini-IGFBP-5 domains. Since the KD
values for mini-IGFBP-5 and the 10 kDa fragment do not
differ significantly, residues located at the C-terminal from
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the 10 kDa segment (residues 105–246) must be involved
in the additional stabilization of the IGF complexation in
the intact IGFBP-5 protein. These findings are consistent
with a recent study of IGF binding in IGFBP-4 (Qin et al.,
1998). Deletion analysis using IGFBP-4 expressed in
bacteria revealed that the N-terminal sequence Leu72–
Ser91 was essential for IGF binding. The C-terminal
fragments (His121–Glu237 or Arg142–Glu237) did not
bind to IGF but loss of these regions decreased IGF-
binding activity. Detailed deletion analysis identified the
residues Cys205–Val214 as the motif to facilitate IGF
binding (Qin et al., 1998). Our BIAcore and NMR IGF-
binding data indicate a common principle for the binding
of IGFs by all IGFBPs. This model is consistent with
recent reports on the IGF binding of fragments of
IGFBP-3 (Fowlkes et al., 1995; Hashimoto et al., 1997)
and IGFBP-4 (Chernausek et al., 1995; Qin et al., 1998),
using methods other than BIAcore and NMR, but contra-
dicts reports that indicated substantial IGF binding in the
C-domain of IGFBP-3 (residues 151–263) (Wang et al.,
1988; Spencer and Chan, 1995) and IGFBP-2 (Ho et al.,
1997).
Although the structure of the mini-IGFBP-5–IGF com-
plex would be the most desirable for explaining inter-
Structural basis of the IGFBP-5 binding to IGFs
Fig. 8. The F1–F2 stripes of the 13C-1H NOESY-HSQC spectra of the
IGF-II–mini-IGFBP-5 complex at the 1H methyl frequencies of
residues 49, 73, 74 and 91 of mini-IGFBP-5 showing their NOEs to
residues of mini-IGFBP-5 and IGF-II (blue) and intermolecular NOEs
to IGF-II (red).
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Table III. Average deviations from ideality, energies of the structures,
and r.m.s.d. between experimental and calculated distance constraints
Parameter SA
Deviations from idealized geometry
bonds (Å) 0.006  0.001
angles (deg.) 0.706  0.030
impropers (deg.) 0.498  0.036
Energies (kcal/mol)
ENOE 29.4  4.5
Etor 2.2  0.3
EvdW 6.1  0.7
Number of residual constraint violations for all constraints
0.3 Å r.m.s.d. 0.4 Å 4.0  2.3
0.4 Å r.m.s.d. 0.5 Å 0.1  0.2
0.5 Å 0.0
r.m.s.d. from experimental distance constraints (Å)
all (384) 0.048  0.009
interresidue (|i–j|5) (221) 0.030  0.007
long-range (112) 0.054  0.006
H-bond distances (8) 0.050  0.008
intraresidue (32) 0.046  0.007
intraresidue (32) 0.046  0.007
SA represents the ensemble of the 20 final structures. Force
constants used to calculate energy terms are the same as reported
previously (Holak et al., 1989). The r.m.s.d. from the interproton
distance constraints were calculated as described in Holak et al.
(1989). The number of distance constraints is given in parentheses.
actions between IGFBPs and IGFs, it has so far proved
elusive, possibly because of a tendency for the complex
to aggregate. However, our NMR mapping study of mini-
IGFBP-5 together with mutagenesis studies of IGFs
enables modelling of the IGF–IGBP interaction with a
high degree of confidence. A number of hydrophobic
residues, Val49, Leu70 and Leu74, expose their side-
chains into solution defining a hydrophobic patch on the
surface of mini-IGFBP-5 (Figures 5 and 7). Several
intermolecular NOE connectivities were observed from
these residues to the proton resonances of the aromatic
side-chains of IGF-II (Figure 8). Site-directed mutagenesis
studies on IGFs indicate that IGF residues Glu6, Phe48,
Arg49 and Ser50 are important for binding to IGFBPs
(Luthi et al., 1992; Bach et al., 1993; Francis et al., 1993;
Jansson et al., 1997). It was suggested also that Phe26 of
IGFs plays a role in changing the local structures of IGFs
but does not bind directly to IGFBPs (Terasawa et al.,
1994). Thus, Phe48 of IGFs remains the prime aromatic
residue that could bind to the hydrophobic patch of
IGFBP-5. The hydrophobic residues Val49, Leu73 and
Leu74 of IGFBP-5 are highly conserved among all
IGFBPs. We therefore concluded that this hydrophobic
interaction dominates the IGF-binding properties of
IGFBP-5. Based on these considerations, the mini-
IGFBP-5 and IGF-II molecules can be placed in a unique
orientation in the complex so that all experimental data,
and hydrophilic–hydrophobic and electrostatic interactions
are satisfied. The resulting model is presented in Figure 7.
As can be seen from Figure 7, Phe48 of IGF-II could be
docked on the hydrophobic patch of mini-IGFBP-5. The
hydrophilic and acidic Glu6 of IGF-II interacts with the
basic Lys68 of mini-IGBFP-5. Thus, the hydrophobic–
hydrophilic fit is strikingly complementary in the complex,
in agreement with the experimental tight nanomolar bind-
ing between mini-IGFBP-5 and IGF-II. The model may
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be further improved if some conformational rearrange-
ments of the N-terminus of IGF-II and the variable loop
between residues 62 and 69 of mini-IGFBP-5 were
allowed.
In contrast to the conserved hydrophobic patch of the
IGFBPs, the variable loop between residues 62 and 69 is
less conserved and may be responsible for the variations
of affinities to IGFs observed among the IGFBPs. Interes-
tingly, the basic Lys68 of IGFBP-5 is conserved also in
IGFBP-3 and IGFBP-4 (Lys, Arg, respectively). The nature
of these residues differs significantly from the hydrophobic
or neutral residues of IGFBP-1,-2 and -6 (Gln, Leu
and Ala, respectively). This may explain their decreased
affinities to IGFs, since according to our model of the
IGF–IGFBP complex, acidic Glu6 of IGF-II binds to this
region of the IGF-binding protein (Figure 7).
Degradation of IGFBPs by specific IGFBP proteases is
known to occur under a variety of physiological and
pathophysiological conditions (Rajaram et al., 1997) and
therefore the interaction of IGFBP-5 and its fragments with
the IGF-receptor binding and signalling was investigated in
more detail. Ligand binding assays using radiolabelled
IGFs clearly demonstrated that the full-length IGFBP-5
and the N-terminal fragments are able to inhibit the
binding of IGFs to the receptor. In contrast to the relative
affinities determined by biosensor measurements, lower
concentrations of IGFBP-5 than theoretically expected
were sufficient to interfere with receptor binding and
indicate a higher affinity of the complex in solution,
as reported in other studies using radiolabelled binding
partners (Kiefer et al., 1992; Loddick et al., 1998). In
addition to the different experimental conditions of these
assays (temperature, buffers, concentrations) the use of an
immobilized and thereby chemically modified ligand in
the biosensor method may result in reduced apparent
affinities, especially for full-length IGFBP-5. Similar dif-
ferences between biosensor and solution binding assays
were also reported for IGFBP-3 and the apparent affinities
determined by the BIAcore method were dependent on the
experimental conditions and the method of data analysis for
determining the kinetic constants (Sommer et al., 1993;
Heding et al., 1996). It also should be noted that the
comparison of the IGF-II–IGF-IR–IGFBP-5 and IGF-II–
IGFBP-5 complexes is further complicated by the fact
that IGFs appear to undergo a conformational change on
binding to their receptors (Gill et al., 1996; Jansson
et al., 1997).
Upon binding of IGFs to the IGF-IR, the intracellular
part of the receptor undergoes autophosphorylation, which
is a prerequisite for all known IGF-mediated biological
actions. Therefore we used the IGF-mediated receptor
autophosphorylation as a further method to investigate
how the biological action of IGFs is modulated by
IGFBP-5 and its fragments. Surprisingly, intact IGFBP-5
inhibits IGF-stimulated autophosphorylation of the recep-
tor very efficiently and complete inhibition is achieved
when IGFBP-5 is in excess of IGFs. The IC50 values of
IGFBP-5 in this experiment are 100-fold higher than in
the ligand-binding assay because the cell number and IGF
concentration had to be increased to allow detection of
the autophosphorylation of the receptor. In the ligand-
binding assay a 1000-fold higher concentration of frag-
ments than IGFBP-5 was necessary to inhibit the binding
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of IGFs to the cell but we were not able to apply equivalent
increased concentrations of fragments in the receptor
stimulation assay. Therefore, we cannot completely
exclude the possibility that inhibition of receptor stimula-
tion might occur at higher concentrations of the fragments.
The receptor-stimulation assay and the ligand-binding
assay clearly demonstrate that intact IGFBP-5 inhibits the
biological activity of IGFs. N-terminal fragments are still
able to bind IGFs with moderate affinities but they are
only able to inhibit receptor binding at unphysiologically
high concentrations. The affinity of the fragments is much
lower than the affinity of IGF-IR for IGFs and therefore
they are not able to compete with receptor stimulation
under physiological conditions. Accordingly, cleavage of
IGFBP-5 by proteases will result in strongly reduced
affinities of the fragments and thereby increased levels
of free IGFs which are able to stimulate the receptor
signalling.
The observation that a weak inhibitory potency of the
N-terminal fragments of IGFBP-5 does not reflect their
high affinity for IGF-II clearly indicates that the C-terminal
domain of IGFBP-5 has the capacity to enhance the
affinity of the native protein to inhibit IGF activation of
the receptor. Since no primary binding site appears to
exist in the C-terminal domain, the higher affinity of the
full-length protein may result either from low-affinity
binding sites within the C-terminal part of the protein (in
a similar fashion to that found in IGFBP-4; Qin et al.,
1998) or from a structural change of the N-terminal
domain resulting in an increased affinity and inhibition of
receptor binding. However, conformational changes within
the N-terminal domain are unlikely because of the rigid
and compact mini-IGFBP-5 structure (stabilized, for
example, by covalent disulfide bonds, also unchanged in
the 10 kDa fragment). Figure 3A indicates that incomplete
inhibition of receptor binding is observed for the frag-
ments, especially in the case of mini-IGFBP-5, where the
inhibition curve does not drop all the way to zero even at
high concentrations. Therefore, it appears that IGF-II still
binds to the receptor even when complexed to the truncated
IGFBP-5 fragments, which implies that the binding of
IGF-II to its receptor is sterically hindered by the
C-terminal domain of the much larger full-length IGFBP-
5. Additionally, it should be remembered that IGFs appear
to undergo a conformational change on binding to their
receptors (Gill et al., 1996; Jansson et al., 1997).
The inhibition of the stimulation of the IGF receptor
by IGF-I in the presence of full-length IGFBP-5 and the
strongly reduced inhibitory potency of the N-terminal
fragments of IGFBP-5 may account for contradictory
results reported in the literature on the activity of IGFBPs
in different assay systems (Gill et al., 1997; Higo et al.,
1997; Yeh et al., 1997). The stimulation of the IGF-I
activity by IGFBP-5 may be caused either by targeting
IGF-I to the receptor-containing cell surface, by an IGF-
independent effect of the binding protein as shown for
fragments of IGFBP-3 (Gill et al., 1997), or by a fast
degradation during the incubation period in cell culture.
On the other hand, the inhibitory effect of IGFBP-5 on
the growth of carcinoma C33A cells (Higo et al., 1997)
and on the induction of alkaline phosphatase in fetal
rat calvarial cells by OP-1 (Yeh et al., 1997) clearly
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demonstrates the ability of IGFBP-5 to act as an inhibitor
of cell proliferation or differentiation.
Materials and methods
Cloning, protein expression and purification
For subcloning of mini-IGFBP-5 (residues 40–92 of IGFBP-5) and the
His-tag 10 kDa IGFBP-5 domain (residues 1–104) into the BamHI and
PstI restrictions sites of the pQE30-vector (Qiagen, Hilden, Germany)
in-frame to a His-tag, two sets of the following oligonucleotides





Restrictions sites, a stop codon, and in the case of the mini-construct,
21 bases encoding an N-terminal thrombin cleavage site were introduced
using overhangs shown in small letters. Vector (0.2 μg) containing the
complete sequence of IGFBP-5 was used as a template. Conditions for
the PCR reaction were as follows: polymerase Vent (National Biolabs,
UK); 2 mM MgSO4; (92°C for 60 s, 62°C for 60 s, 72°C for 40 s)35
for mini-IGFBP-5; and (92°C for 60 s, 60°C for 60 s, 72°C for 40 s)35
for 10 kDa IGFBP-5. Standard procedures were used for construction
and verification of vectors pQE30 (mini-IGFBP-5) and pQE30 (His-
tag10 kDa IGFBP-5) which were transformed finally into E.coli
strain Bl21(DE3) (Novagen, Canada) for overexpression of tag-mini-
IGFBP-5 which encodes the following amino acid sequence
mrgshhhhhhsglvprGSALA..SYREQVKI and 10 kDa IGFBP-5 which
encodes for mrgshhhhhhsgMVLL...KIERDS. Amino acids of the His-
tag, including the thrombin-cleavage site (underlined), are in italics. Mini-
IGFBP-5 and 10 kDa IGFBP-5 after cleavage by thrombin comprises the
amino acid sequence denoted in capital letters.
Expression was performed for both constructs at 37°C in shaking
cultures at 300 r.p.m. Ampicillin (100 μg per 1 l culture) was used as
the selection antibiotic and expression was induced by 1 mM IPTG at
a cell density of OD600  0.8. Cells were harvested after 4 h by
centrifugation. For protonated samples standard LB-media were used.
Uniformly 15N-labelled and 13C/15N- doubly labelled mini-IGFBP-5
samples were prepared in a M9-minimal medium containing 1 g/l
15N-NH4Cl (Campro, Netherlands) and 10 g glucose as the only nitrogen
and carbon source (Muchmore et al., 1989) or 1 g/l 15N-NH4Cl and
2 g/l 13C6-glucose, supplemented with minerals and cofactors (Hoffman
and Spicer, 1991). For 15N amino acid selective labelling, the minimal
medium (14N) was enriched with unlabelled amino acids and the double
amount of the 15N-labelled amino acid (Muchmore et al., 1989).
Selectively labelled mini-IGFBP-5 in 15N glycine/serine, glycine/serine/
cysteine, alanine/valine and leucine were prepared.
Purification of mini-IGFBP-5 and the His-tag 10 kDa IGFBP-5
The following instructions are referred to a cell material of a 1 l culture
containing ~5 mg mini-IGFBP-5 or 10 mg 10 kDa IGFBP-5 (1–104).
The pelleted cells were resuspended in 20 ml of buffer A (6 M
guanidinium chloride, 100 mM Na3PO4, 10 mM Tris, 10 mM β-
mercaptoethanol pH 8.0) and stirred for 1 h to lyse the cells. This
solution was centrifuged for 1 h at 60 000 g, the supernatant was loaded
on a 5 ml Ni–NTA (Qiagen) column, washed with ~100 ml buffer A,
~100 ml buffer B (buffer A at pH 6.0), and the protein eluted using a
100 ml gradient of buffer B and buffer C (6 M guanidinium chloride,
10 mM β-mercaptoethanol, 100 mM acetate, pH 4.5). Fractions con-
taining mini-IGFBP-5 were pooled, and 0.2 g of DDT was added to
reduce every cysteine bridge. The volume was reduced to 1 ml by
ultrafiltration (Amicon) and dialysed against buffer D (6 M guanidinium
chloride pH 3.0) to remove DDT before diluting into 25 ml of the
refolding buffer E (0.2 M arginine, 1 mM EDTA, 1 mM reduced
glutathione, 1 mM oxidized glutathione, 100 mM Tris pH 8.2). After
14 h at 4°C tag-mini-IGFBP-5 was completely refolded (checked by
reverse-phased chromatography; data not shown). The concentrated
solution was dialysed against buffer F (60 mM NaCl, 60 mM KCl,
2.5 mM CaCl2, 50 mM Tris pH 8.0) in order to cut off the His-tag by
20 units of thrombin (T3010, Sigma, Germany) within 12 h at room
temperature. The samples were then dialysed against buffer G (50 mM
Tris pH 8.0) and loaded on an anion exchange column (DE 52, Whatman).
The flow-through contained the pure protein, mini-IGFBP-5. A final gel
filtration was performed on Superdex75 (Pharmacia) in buffer H (100 mM
Na2PO4, 200 mM NaCl pH 5.0).
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For the His-tag 10 kDa IGFBP-5, the purification and refolding was
identical except that the thrombin proteolysis was not carried out. The
NMR samples were measured at pH 4.5 in 20 mM phosphate buffer,
50 mM NaCl, 1 mM EDTA and 10% D2O.
Proteolytic digest of IGFBP-5
Recombinant human IGFBP-5 was produced in E.coli as described by
Mohan et al. (1995). Proteolytic fragments of IGFBP-5 were produced
by incubation of IGFBP-5 with endoproteinase Asp N (Boehringer
Mannheim) (200:1; w/w) in 20 mM Na2PO4 pH 7.0 for 4 h at 26°C.
Fragments were isolated after addition of urea (up to 7 M) by separation
using S–Sepharose (Pharmacia). The C-terminal 17 kDa fragment was
eluted with a gradient from 0–0.5MNaCl and dialysed against phosphate-
buffered saline (PBS). The 10 and 4 kDa fragments, which passed
through the column, were separated by hydroxyapatite chromatography
(Macro Prep, Bio-Rad).
BIAcore analysis
BIAcore 2000, Sensor Chip SA and HBS were obtained from BIAcore
AB (Uppsala, Sweden). All experiments were performed at 25°C and
HBS was used as a running buffer and for the dilution of ligands and
analytes. Biotinylated IGF-I was immobilized at a concentration of 5
and 10 nM in HBS at a flow rate of 5 μl/min to the streptavidin-coated
sensor chip resulting in signals of 40 and 110 resonance units (RU).
Biotinylated IGF-II was immobilized at a concentration of 5 nM in HBS
resulting in a signal of 20 RU. An empty flow cell was used as control
for unspecific binding and bulk effects. The low ligand concentration
was necessary to limit mass-transport limitations and rebinding. For the
same reason all kinetic experiments were performed at the highest
possible flow rate of 100 μl/min. Each solution (IGFBP-5, mini-IGFBP-
5 and the N-terminal 10 kDa fragment) was injected at four concentrations
(250, 50, 10 and 2 nM). Each sample was injected for 2 min followed
by dissociation in buffer flow for 4 min. After the dissociation phase
the sensor chip was regenerated by injection of 10 μl of 100 mM HCl
at a flow rate of 5 μl/min. The kinetic parameters were calculated using
the BIAevaluation 3.0 software (BIAcore AB). After subtraction of the
blank sensorgram the kinetic rate constants were calculated from a
general fit of an overlay of the sensorgrams of all concentration of one
analyte using the method called ‘1:1 binding with mass transfer’. IGF-I
and IGF-II were biotinylated with a 5-fold molar excess of D-biotinyl-
ε-aminocaproic acid-N-hydroxysuccinimide ester using the reagents and
the operation instructions of the Biotin Protein Labelling Kit (Boehringer
Mannheim GmbH). After blocking with lysine, the reaction mixture was
dialysed against 50 mM Na2PO4, 50 mM NaCl pH 7.5.
Ligand binding
NIH 3T3 cells stably expressing human IGF-IR (kindly provided by
Axel Ullrich) were grown in culture dishes in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10% fetal calf serum. Cells were
washed carefully with PBS and incubated with 5 ml of 50 mM EDTA
in PBS for 45 min. Cells were removed from the plate, washed once
with PBS and once with binding buffer (100 mM HEPES pH 7.6,
120 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1 mM EDTA, 10 mM
glucose, 15 mM sodium acetate, 1% dialysed BSA), and resuspended in
binding buffer to determine the cell number. Then 5 pM 125I-IGF-I
or 5 pM 125I-IGF-II (Amersham) was preincubated with increasing
concentrations of the different IGF-binding proteins from 0 to 110–6
M at 4°C for 1 h and then added to 400 μl of the cell suspension
corresponding to 2105 cells to give a total volume of 500 μl. After
12 h incubation at 4°C, cells were washed with binding buffer (at 4°C).
Free hormone was removed by repeated centrifugation and resuspension
in the binding buffer. The 125I radioactivity bound to the cells was
determined in a γ-counter.
Receptor phosphorylation
Confluent monolayers of the NIH 3T3 cells stably expressing human
IGF-IR in 3.5 cm dishes were starved in DMEM containing 0.5%
dialysed fetal calf serum. After 48 h, cells were incubated without any
hormone or with 510–9 M IGF-I or 110–8 M IGF-II; each sample
was preincubated with increasing concentrations of different IGF-binding
proteins from 0 to 110–6 M at room temperature for 1 h. After a
10 min stimulation at 37°C, the medium was removed and cells were
lysed with 250 μl of lysing buffer (20 mM HEPES pH 7.5, 150 mM
NaCl, 10% glycerol, 1% NP-40, 1.5 mM MgCl2, 1 mM EGTA),
10 mM sodium orthovanadate, and protease inhibitor cocktail Complete
(Boehringer Mannheim) for 10 min on ice. Subsequently, cells were
scraped off the plate and the insoluble material was separated by
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centrifugation for 20 min at 4°C. The protein concentration of the
supernatant was determined using the BCA kit from Pierce according
to the manufacturer’s instructions. Equal protein concentration was
incubated with the SDS sample buffer (63 mM Tris–HCl pH 6.8, 3%
SDS, 10% glycerol, 0.05% bromophenolblue, 100 mM DTT), boiled for
5 min and loaded on a 7.5% SDS–polyacrylamide gel. After electrophor-
esis the proteins were transferred on a nitrocellulose membrane which
first was blocked for 1 h with the 3% BSA containing phosphate-
buffered saline–Tween (PBST), then incubated overnight with 1 μg/
ml monoclonal anti-phosphotyrosine antibody 3-365-10 (Boehringer
Mannheim) in PBST that contained 3% BSA. Unbound antibody was
removed by extensive washing. The blot was then incubated with
1:10 000 diluted anti-mouse IgG-specific antibody conjugated with
horse radish peroxidase (Boehringer Mannheim). The immunoblot was
developed using the ECL kit from Amersham.
NMR spectroscopy
NMR experiments were carried out at 304 K on Bruker AMX 500, DRX
600 and DMX 750 spectrometers. All spectrometers were equipped with
triple resonance (1H, 13C, 15N) probeheads and pulsed-field gradient
(PFG) accessories. Triple resonance [CBCA(CO)NH; Grzesiek and Bax,
1992a; CT-HNCA, CT-HNCO Grzesiek and Bax, 1992b], 3D 1H-15N
NOESY-HSQC, 3D 1H-15N TOCSY-HSQC, 3D 1H-13C NOESY-HSQC
and 3D HCCH-TOCSY experiments (Bax and Grzesiek, 1993; Kay
et al., 1993; Edison et al., 1994) were recorded for both the uncomplexed
and the IGF-II-complexed form of mini-IGFBP-5. For non-selective
inversion of 13C longitudinal magnetization hard power, square pulses
were replaced by adiabatic pulses (Silver et al., 1984; Kupce and
Freeman, 1995). Isotropic mixing (Braunschweiler and Ernst, 1983) was
performed with DIPSI-2 and DIPSI-3 spin-lock sequences (Shaka et al.,
1988). Water suppression in experiments recorded on samples in H2O
was achieved by incorporation of a WATERGATE sequence (Sklenar
et al., 1993) into the various pulse sequences. Residual water in
experiments measured on samples in D2O was removed by application
of a weak presaturation field of 15 Hz. Quadrature detection in all
indirectly detected dimensions was obtained through STATES-TPPI
phase cycling (Marion et al., 1989). Triple resonance experiments, 2D
TOCSY (τm  62 ms), 3D
1H-15N TOCSY-HSQC (τm  62 ms), long
mixing time 2D NOESY (τm  120 ms) and long mixing time 3D
1H-
15N NOESY-HSQC (τm  120 ms) experiments in H2O were recorded
as water flip-back versions employing either carefully selected pulse
phases (Jahnke et al., 1995; Stonehouse et al., 1995), selective pulses
on water (Lippens et al., 1995; Dhalluin et al., 1996) or constructive
radiation damping (Talluri and Wagner, 1996). The 3D 1H-15N TOCSY-
HSQC (τm  62 ms) experiment was modified according to the 2D
water flip-back TOCSY for achieving minimal saturation of water
(Dhalluin et al., 1996). In short mixing time 2D NOESY experiments
zero-quantum coherence contributions were reduced by varying the
mixing time randomly for every individual transient of each FID (Hull,
1994). Side-chain resonances were assigned using 2D NOESY (τm 
120 ms) in D2O, 3D
15N-edited TOCSY (τm  62 ms) and 3D HCCH-
TOCSY (τm  19 ms) experiments. Stereospecific assignments were
obtained from a combination of 2D DQF-COSY (Rance et al., 1983) in
D2O, short mixing time 2D NOESY in H2O and D2O (τm  14 ms 
4 ms), 2D 1HN-15N-[13Cγ] difference HSQC (Hu and Bax, 1997a), 3D
HN(CO)C (Hu and Bax, 1997b) and 2D 13C-[13Cγ[aromatics]] spin-echo
difference together with 2D 15N-[13C [aromatics]] spin-echo difference
1HN-15N HSQC experiments (Hu et al., 1997). χ1 angles in valine,
isoleucine, and threonine residues were determined by 2D spin-echo
difference CT-HSQC and 2D long-range 13C-13C correlation experiments
(Bax et al., 1994). Side-chain amide protons of asparagine and glutamine
residues were assigned stereospecifically with a 2D H2NCO-E.COSY
(Lo¨hr and Ru¨terjans, 1997). Presence of multiple conformations was
ruled out by a combination of short mixing time 2D NOESY (τm  14
ms  4 ms), 2D TOCSY (τm  62 ms) and 2D ROESY (Brown and
Farmer, 1989) (τm 50 ms) spectra in D2O. The state of oligomerization
was investigated with two 2D 15N double-half-filtered NOESYs (Otting
and Wu¨thrich, 1990) (τm  120 ms) at pHs 4.5 and 3.9 in H2O and
with a 2D 13C double-half-filtered NOESY (τm  120 ms) experiment
utilizing optimized WURST inversion pulses for suppression of signals
from 13C-labelled molecules in D2O (Folmer et al., 1995; Zwahlen
et al., 1997). The 2D 15N double-half-filtered NOESY sequence was
transformed into a water flip-back version by incorporation of selective
pulses on water. The complexation of mini-IGFBP-5 with IGF-II was
investigated with 3D 13C F1-filtered, F3-edited NOESY-HSQCs (τm 
150 ms) in H2O and D2O (Zwahlen et al., 1997). 2D
1H-15N HSQC
spectra with reduced signal loss due to the fast chemical exchange were
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recorded using procedures described by Mori et al. (1995). Exchange
rates of 1H-15N-bound protons were measured by recording a series of
2D 1H-15N HSQC spectra at 25 and 35 min; 1, 2, 4 and 10 h; 1 and 3
days, 1 week and 1 month after dissolving the protein in D2O. All 3D
spectra were processed and evaluated with the software CC-NMR
(Cieslar et al., 1993). Resolution in the indirect dimensions was increased
by linear prediction and zero-filling (Edison et al., 1994). The 1H-15N
heteronuclear NOE measurements were carried out using the pulse
sequence of Farrow et al. (1994). Saturation of the amide protons in the
heteronuclear NOE experiment was achieved by the application of a
series of 120° pulses prior to the experiment (Farrow et al., 1994).
Intensities of the cross peaks in the NOE spectrum were obtained from
the peak heights.
Assignment and structure calculation
Assignment, data-handling and control of X-PLOR-calculations
(Bru¨nger, 1993; Bru¨nger and Nilges, 1993) were performed using our
software NMRscout, which is based on CC-NMR (Cieslar et al., 1993).
NOEs were derived from the 2D NOESY spectra in H2O and D2O, from
the 15N-edited and the 13C-edited NOESY spectra. Peak heights were
used for quantification of peak intensities. Four classes of NOEs were
distinguished: 4.2 Å for a weak, 3.5 Å for a medium, 2.8 Å for a
medium-strong and 2.3 Å for a strong NOE-signal. Sequential Hα(i)-
HN(i	1) signals within β-elements were rated as strong NOEs; other
NOE intensities were then ascribed according to this internal calibration.
The upper and lower boundaries (in parentheses) for these distance
restraints were set to 0.8 Å (0.6), 0.5 Å (0.5), 0.4 Å (0.4) and 0.4 Å
(0.4), respectively. All protons were explicitly defined in the dynamic
simulated annealing calculations; in some cases, however, additional
terms were added to the upper bounds as a pseudoatom correction
(Wu¨thrich, 1986).
The distance constraints were then supplemented with 44 φ torsion
angle constraints derived from HNHA, HN(CO)CO and HN(CO)C
experiments (Vuister and Bax, 1993; Hu and Bax, 1996; Hu and Bax,
1997b). At the final stage, two ω angles for the trans-peptide bond of
the X-Pro residues, together with 34 χ1 restraints were added. Structure
calculations were performed using standard protocols (Holak et al.,
1989) for simulated annealing and distance geometry constraint methods
implemented in the program X-PLOR.
Binding of IGF-II to IGFBP-5
The 1H-15N- and 1H-13C-HSQC spectra of mini-IGFBP-5 complexed to
IGF-II and IGF-I were assigned independently on the basis of two sets
of CT-HNCA, CBCA(CO)NH, CT-HNCO and 15N-separated NOESY-
HSQC spectra. HSQC spectra were successively recorded for mixtures
of mini-IGFBP-5 and IGFs with IGF concentrations of 0, 10, 20, 40,
60, 80, 100 and 120% relative to mini-IGFBP-5. All IGF-induced shifts
S(i)atom of one atom-type (for example,
1H backbone and side-chain
proton atoms) and residue i were combined and averaged to S(i)H, S(i)C
and S(i)N. Different sensitivities of chemical shifts of proton, nitrogen
and carbon atoms were considered by introducing scaling factors fAtom
with fH1, fN0.2 and fC0.5 so that the scaled shift SN(i)atom
was calculated as SN(i)atomfAtomS(i)atom. Combinations of shifts
SN(i)(atom,atom) of different atom types were calculated by averaging
SNatom [e.g. SN(i)(HC)  (SN(i)H wH	SN(i)C wc)/(wH	wc), where
watom is a weighting factor, wHwc2, wN1; see Figure 6]. The error
in chemical shift is estimated to be 0.01 p.p.m.
The docking experiments for the model of the IGF-II and mini-
IGBP-5 complex were carried out with the Insight II program using the
coordinates of IGF-II found in entry 1IGL (PDB data bank) (Torres
et al., 1995). Twenty structures for each IGF-II and mini-IGFBP-5 have
been docked manually with each other assuming the binding sites
determined experimentally (see Results). The resulting complexes were
subjected to energy minimization with the Discover programme. Thirty
lowest energy structures that were chosen had their final energies close
to each other (93  12 kcal/mol). Figure 7 shows the model for the
lowest energy calculation.
Supplementary material
Supplementary material available from the authors consists of a table
with the 1H, 13C and 15N chemical shifts of mini-IGFBP-5. The
coordinates of mini-IGFBP-5 together with a complete list of NOE,
hydrogen-bond and torsion angle constraints have been deposited in the
Brookhaven Data Bank.
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